- Home
- ZVSA vs HSCS Comparison
ZVSA vs HSCS Comparison
Compare ZVSA & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- HSCS
- Stock Information
- Founded
- ZVSA 2014
- HSCS 2007
- Country
- ZVSA United States
- HSCS United States
- Employees
- ZVSA N/A
- HSCS N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- ZVSA Health Care
- HSCS Health Care
- Exchange
- ZVSA Nasdaq
- HSCS Nasdaq
- Market Cap
- ZVSA 3.5M
- HSCS 2.8M
- IPO Year
- ZVSA N/A
- HSCS 2022
- Fundamental
- Price
- ZVSA $0.59
- HSCS $2.80
- Analyst Decision
- ZVSA Strong Buy
- HSCS Strong Buy
- Analyst Count
- ZVSA 1
- HSCS 2
- Target Price
- ZVSA $240.00
- HSCS $13.00
- AVG Volume (30 Days)
- ZVSA 125.6K
- HSCS 13.0K
- Earning Date
- ZVSA 05-14-2025
- HSCS 03-13-2025
- Dividend Yield
- ZVSA N/A
- HSCS N/A
- EPS Growth
- ZVSA N/A
- HSCS N/A
- EPS
- ZVSA N/A
- HSCS N/A
- Revenue
- ZVSA N/A
- HSCS N/A
- Revenue This Year
- ZVSA N/A
- HSCS N/A
- Revenue Next Year
- ZVSA N/A
- HSCS N/A
- P/E Ratio
- ZVSA N/A
- HSCS N/A
- Revenue Growth
- ZVSA N/A
- HSCS 261.17
- 52 Week Low
- ZVSA $0.58
- HSCS $2.36
- 52 Week High
- ZVSA $8.05
- HSCS $13.50
- Technical
- Relative Strength Index (RSI)
- ZVSA 27.23
- HSCS 40.13
- Support Level
- ZVSA $0.69
- HSCS $2.75
- Resistance Level
- ZVSA $0.65
- HSCS $2.95
- Average True Range (ATR)
- ZVSA 0.06
- HSCS 0.15
- MACD
- ZVSA -0.00
- HSCS 0.00
- Stochastic Oscillator
- ZVSA 3.04
- HSCS 11.90
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.